Radiotherapy for Hodgkin's lymphoma: too hard to die? (Journal article)

Zygogianni, A. G./ Kyrgias, G./ Psyrri, A./ Kantzou, I./ Koumarianou, A./ Tolia, M./ Tsekeris, P./ Tsirigotis, P./ Sarris, G./ Kouvaris, J./ Kouloulias, V.

The treatment of Hodgkin's lymphoma (HL) is associated with significant toxicity. The objective of high quality management is to keep the concept of combined modality, while trying to decrease the radiation dose, to diminish to a great extent the irradiated volume and at the same time to reduce the number of chemotherapy courses, introducing the so-called optimisation. New directives should be followed to obtain more effective treatments of HL. Shorter cycles of chemotherapy and the utilization of modern techniques in radiotherapy (RT) constitute fundamental steps to achieve this objective. Analysis of randomized studies supports the inclusion of reduced-field and dose of RT in the radiotherapeutic treatment options for HL. RT is an integral part of the combined-modality therapy (CMT) of HL.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών
Keywords: chemotherapy,hodgkin's lymphoma,new agents,radiotherapy,stem-cell-transplantation,high-dose chemotherapy,involved-field radiotherapy,intensity-modulated radiotherapy,bone-marrow transplantation,combined-modality therapy,radiation-therapy,conventional chemotherapy,randomized trial,clinical-trials
ISSN: 1107-0625
Link: <Go to ISI>://000302503700019
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.